Squamous-cell carcinoma of the lung: molecular subtypes and therapeutic opportunities
Cet article passe en revue les perspectives offertes par la caractérisation moléculaire des tumeurs de patients atteints d'un carcinome épidermoïde du poumon pour le développement de biomarqueurs de réponse à des thérapies ciblées
Lung cancer is the leading cause of cancer-related death worldwide. Squamous-cell carcinoma (SCC) of the lung is, behind adenocarcinoma, the second most frequent histology in non-small cell lung cancer. Encouraging new treatments benefit the adenocarcinoma population (ie bevacizumab, EGFR tyrosine kinase inhibitors, ALK inhibitors) but, unfortunately, the same is not true for squamous cell carcinoma. However many genomic abnormalities are present in SCC and there is growing evidence of the biological significance of them. Therefore molecular characterization of patients with SCC in modern profiling platforms will probably be, in the short term, as important as adenocarcinoma molecular deciphering. Patients with SCC of the lung harboring specific molecular defects that are actionable (ie FGFR1 amplification, DDR2 mutation, PI3K amplification, etc) should be enrolled in prospective clinical trials targeting such molecular defects.
Clinical Cancer Research , résumé, 2012